Seattle Genetics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
September 03 2020 - 8:00AM
Business Wire
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that
management will participate in a fireside chat during the virtual
Morgan Stanley 18th Annual Global Healthcare Conference on Tuesday,
September 15, 2020 at 3:30 p.m. Eastern Time. The presentation will
be webcast live and available for replay from Seattle Genetics’
website at www.seattlegenetics.com in the Investors section.
About Seattle Genetics
Seattle Genetics, Inc. is a global biotechnology company that
discovers, develops and commercializes transformative cancer
medicines to make a meaningful difference in people’s lives.
ADCETRIS® (brentuximab vedotin) and PADCEV® (enfortumab
vedotin-ejfv) use the Company’s industry-leading antibody-drug
conjugate (ADC) technology. ADCETRIS is approved in certain
CD30-expressing lymphomas, and PADCEV is approved in certain
metastatic urothelial cancers. TUKYSA® (tucatinib), a small
molecule tyrosine kinase inhibitor, is approved in certain
HER2-positive metastatic breast cancers. The Company is
headquartered in the Seattle, Washington area, with locations in
California, Switzerland and the European Union. For more
information on our robust pipeline, visit www.seattlegenetics.com
and follow @SeattleGenetics on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200903005249/en/
Investors: Peggy Pinkston (425) 527-4160
ppinkston@seagen.com
Media: Monique Greer (425) 527-4641 mgreer@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024